CA-BOLT
18.6.2024 15:03:34 CEST | Business Wire | Press release
Stellantis Financial Services US, the captive automotive finance company of Stellantis in North America, today announced a new partnership with bolt, the insurtech with the world’s largest technology-enabled insurance exchange, to support customers of Chrysler, Dodge, Jeep®, Ram, Fiat, and Alfa Romeo. bolt’s technology will enable Stellantis customers to purchase auto insurance through Stellantis brand websites and mobile apps with a panel of insurers’ products.
Through this unique partnership, the automotive insurance purchasing journey will be simplified and personalized, with custom coverage options available through multiple distribution channels. The offering will scale to include usage-based choices through the use of telematics, data and analytics.
“Stellantis customers today want choice, context, and simplicity when selecting their auto insurer,” said Mark Buffa, Managing Director of Insurance at Stellantis Financial Services US. “It’s important that insurance offerings keep up with customer demands. Partnering with bolt and their established insurer partners, we’re confident that customers and their vehicles will be better protected.”
“We are thrilled with this new partnership which reflects the Stellantis strategy to provide affordable insurance solutions and accident management solutions,” said Edouard de Lamarzelle, CEO of Stellantis Insurance.
Stellantis is focused on developing, engineering, manufacturing and scaling the best breakthroughs in all facets of sustainable mobility.
“Stellantis has an ambitious vision for how insurance can enhance their customers’ experience,” said Rob Bauer, Chief Strategic Growth Officer at bolt. “We’re honored to join Stellantis on this multi-year journey and help write the future of embedded insurance.”
By bridging the gap between all parties in the insurance ecosystem, bolt is developing modern methods of delivering insurance to customers at the point of need. bolt has grown its platform to include more than 100 insurance providers, including eight of the top 10 property and casualty insurers in the United States. With more than US$50 billion in quoted premiums on the platform annually, bolt offers over 6,000 insurance product variations and has licenses across all 50 states.
To learn more about Stellantis Financial Services, please visit www.stellantis-fs.com. To learn more about bolt, visit https://www.boltinsurance.com/.
About Stellantis Financial Services US
Stellantis Financial Services US (SFS) is wholly owned by Stellantis N.V. (NYSE: STLA / Euronext Milan: STLAM / Euronext Paris: STLAP), one of the world’s leading automakers aiming to provide clean, safe and affordable freedom of mobility to all. SFS provides finance solutions for Stellantis' premier automotive brands in the United States including: Chrysler, Dodge, Jeep®, Ram, FIAT, and Alfa Romeo.
About bolt
bolt is the leading distribution platform for P&C insurance, uniting distributors and insurers to transform the way insurance is bought and sold.
The result is the world's largest tech-enabled exchange of insurance products, including two-thirds of America's leading insurers, helping businesses of all kinds distribute insurance, expand market reach, and meet more of the insurance and protection needs of customers.
For more information, visit boltinsurance.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618838215/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom